Examining Endothelial Function and Platelet Reactivity in Patients with Depression before and after SSRI Therapy

Area of Science:

• Cardiovascular Medicine
• Neuroscience
• Pharmacology

Background:

• Major depressive disorder (MDD) is linked to increased cardiovascular disease (CVD) risk.
• Endothelial dysfunction is an early indicator of CVD.
• Mechanisms connecting MDD and CVD risk are not fully understood.

Purpose of the Study:

• To investigate the impact of serotonin-specific reuptake inhibitor (SSRI) therapy on endothelial function in patients with MDD.
• To assess changes in vascular and platelet reactivity markers during SSRI treatment.
• To identify predictors of SSRI treatment response in MDD patients.

Main Methods:

• Assessed endothelial function using flow-mediated dilatation and laser Doppler velocimetry in 31 MDD patients before and after SSRI therapy.
• Measured plasma levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, soluble P-selectin, and noradrenaline.
• Evaluated depression symptom severity using the Hamilton Rating Scale.

Main Results:

• SSRI therapy significantly reduced depression symptoms (P < 0.001) with 19 patients recovered and 4 remitted.
• No significant changes were observed in endothelial function, vascular markers, or platelet reactivity post-SSRI treatment.
• Baseline noradrenaline concentration independently predicted improvement in depression symptoms (r² = 0.36, P = 0.003), with lower levels in responders.

Conclusions:

• SSRI therapy effectively alleviates depression symptoms in MDD patients.
• SSRI treatment did not alter endothelial function or vascular/platelet markers in this cohort.
• Pre-treatment noradrenaline levels may predict SSRI treatment efficacy in MDD.